Aurora Kinase A-Europe Market Status and Trend Report 2013-2023
Report Summary
Aurora Kinase A-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Aurora Kinase A industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Aurora Kinase A 2013-2017, and development forecast 2018-2023
Main market players of Aurora Kinase A in Europe, with company and product introduction, position in the Aurora Kinase A market
Market status and development trend of Aurora Kinase A by types and applications
Cost and profit status of Aurora Kinase A, and marketing status
Market growth drivers and challenges
The report segments the Europe Aurora Kinase A market as:
Europe Aurora Kinase A Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Aurora Kinase A Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
AMG-900
Danusertib
ENMD-2076
Ilorasertib
Others
Europe Aurora Kinase A Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Ovarian Cancer
Anaplastic Large Cell Lymphoma
Brain Tumor
Others
Europe Aurora Kinase A Market: Players Segment Analysis (Company and Product introduction, Aurora Kinase A Sales Volume, Revenue, Price and Gross Margin):
AbbVie Inc.
Amgen Inc.
Astex Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Sanofi
Sareum Holdings Plc
Sigma-Tau S.p.A.
Taiho Pharmaceutical Co., Ltd.
Vertex Pharmaceuticals Incorporated
Vichem Chemie Research Ltd.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Aurora Kinase A-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Aurora Kinase A industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Aurora Kinase A 2013-2017, and development forecast 2018-2023
Main market players of Aurora Kinase A in Europe, with company and product introduction, position in the Aurora Kinase A market
Market status and development trend of Aurora Kinase A by types and applications
Cost and profit status of Aurora Kinase A, and marketing status
Market growth drivers and challenges
The report segments the Europe Aurora Kinase A market as:
Europe Aurora Kinase A Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Aurora Kinase A Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
AMG-900
Danusertib
ENMD-2076
Ilorasertib
Others
Europe Aurora Kinase A Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Ovarian Cancer
Anaplastic Large Cell Lymphoma
Brain Tumor
Others
Europe Aurora Kinase A Market: Players Segment Analysis (Company and Product introduction, Aurora Kinase A Sales Volume, Revenue, Price and Gross Margin):
AbbVie Inc.
Amgen Inc.
Astex Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Sanofi
Sareum Holdings Plc
Sigma-Tau S.p.A.
Taiho Pharmaceutical Co., Ltd.
Vertex Pharmaceuticals Incorporated
Vichem Chemie Research Ltd.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF AURORA KINASE A
1.1 Definition of Aurora Kinase A in This Report
1.2 Commercial Types of Aurora Kinase A
1.2.1 AMG-900
1.2.2 Danusertib
1.2.3 ENMD-2076
1.2.4 Ilorasertib
1.2.5 Others
1.3 Downstream Application of Aurora Kinase A
1.3.1 Ovarian Cancer
1.3.2 Anaplastic Large Cell Lymphoma
1.3.3 Brain Tumor
1.3.4 Others
1.4 Development History of Aurora Kinase A
1.5 Market Status and Trend of Aurora Kinase A 2013-2023
1.5.1 Europe Aurora Kinase A Market Status and Trend 2013-2023
1.5.2 Regional Aurora Kinase A Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Aurora Kinase A in Europe 2013-2017
2.2 Consumption Market of Aurora Kinase A in Europe by Regions
2.2.1 Consumption Volume of Aurora Kinase A in Europe by Regions
2.2.2 Revenue of Aurora Kinase A in Europe by Regions
2.3 Market Analysis of Aurora Kinase A in Europe by Regions
2.3.1 Market Analysis of Aurora Kinase A in Germany 2013-2017
2.3.2 Market Analysis of Aurora Kinase A in United Kingdom 2013-2017
2.3.3 Market Analysis of Aurora Kinase A in France 2013-2017
2.3.4 Market Analysis of Aurora Kinase A in Italy 2013-2017
2.3.5 Market Analysis of Aurora Kinase A in Spain 2013-2017
2.3.6 Market Analysis of Aurora Kinase A in Benelux 2013-2017
2.3.7 Market Analysis of Aurora Kinase A in Russia 2013-2017
2.4 Market Development Forecast of Aurora Kinase A in Europe 2018-2023
2.4.1 Market Development Forecast of Aurora Kinase A in Europe 2018-2023
2.4.2 Market Development Forecast of Aurora Kinase A by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Aurora Kinase A in Europe by Types
3.1.2 Revenue of Aurora Kinase A in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Aurora Kinase A in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Aurora Kinase A in Europe by Downstream Industry
4.2 Demand Volume of Aurora Kinase A by Downstream Industry in Major Countries
4.2.1 Demand Volume of Aurora Kinase A by Downstream Industry in Germany
4.2.2 Demand Volume of Aurora Kinase A by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Aurora Kinase A by Downstream Industry in France
4.2.4 Demand Volume of Aurora Kinase A by Downstream Industry in Italy
4.2.5 Demand Volume of Aurora Kinase A by Downstream Industry in Spain
4.2.6 Demand Volume of Aurora Kinase A by Downstream Industry in Benelux
4.2.7 Demand Volume of Aurora Kinase A by Downstream Industry in Russia
4.3 Market Forecast of Aurora Kinase A in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AURORA KINASE A
5.1 Europe Economy Situation and Trend Overview
5.2 Aurora Kinase A Downstream Industry Situation and Trend Overview
CHAPTER 6 AURORA KINASE A MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Aurora Kinase A in Europe by Major Players
6.2 Revenue of Aurora Kinase A in Europe by Major Players
6.3 Basic Information of Aurora Kinase A by Major Players
6.3.1 Headquarters Location and Established Time of Aurora Kinase A Major Players
6.3.2 Employees and Revenue Level of Aurora Kinase A Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 AURORA KINASE A MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AbbVie Inc.
7.1.1 Company profile
7.1.2 Representative Aurora Kinase A Product
7.1.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of AbbVie Inc.
7.2 Amgen Inc.
7.2.1 Company profile
7.2.2 Representative Aurora Kinase A Product
7.2.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Amgen Inc.
7.3 Astex Pharmaceuticals, Inc.
7.3.1 Company profile
7.3.2 Representative Aurora Kinase A Product
7.3.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Astex Pharmaceuticals, Inc.
7.4 CASI Pharmaceuticals Inc.
7.4.1 Company profile
7.4.2 Representative Aurora Kinase A Product
7.4.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of CASI Pharmaceuticals Inc.
7.5 Merck & Co., Inc.
7.5.1 Company profile
7.5.2 Representative Aurora Kinase A Product
7.5.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.6 Millennium Pharmaceuticals, Inc.
7.6.1 Company profile
7.6.2 Representative Aurora Kinase A Product
7.6.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals, Inc.
7.7 Sanofi
7.7.1 Company profile
7.7.2 Representative Aurora Kinase A Product
7.7.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Sanofi
7.8 Sareum Holdings Plc
7.8.1 Company profile
7.8.2 Representative Aurora Kinase A Product
7.8.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Sareum Holdings Plc
7.9 Sigma-Tau S.p.A.
7.9.1 Company profile
7.9.2 Representative Aurora Kinase A Product
7.9.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Sigma-Tau S.p.A.
7.10 Taiho Pharmaceutical Co., Ltd.
7.10.1 Company profile
7.10.2 Representative Aurora Kinase A Product
7.10.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Taiho Pharmaceutical Co., Ltd.
7.11 Vertex Pharmaceuticals Incorporated
7.11.1 Company profile
7.11.2 Representative Aurora Kinase A Product
7.11.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Vertex Pharmaceuticals Incorporated
7.12 Vichem Chemie Research Ltd.
7.12.1 Company profile
7.12.2 Representative Aurora Kinase A Product
7.12.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Vichem Chemie Research Ltd.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AURORA KINASE A
8.1 Industry Chain of Aurora Kinase A
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AURORA KINASE A
9.1 Cost Structure Analysis of Aurora Kinase A
9.2 Raw Materials Cost Analysis of Aurora Kinase A
9.3 Labor Cost Analysis of Aurora Kinase A
9.4 Manufacturing Expenses Analysis of Aurora Kinase A
CHAPTER 10 MARKETING STATUS ANALYSIS OF AURORA KINASE A
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Aurora Kinase A in This Report
1.2 Commercial Types of Aurora Kinase A
1.2.1 AMG-900
1.2.2 Danusertib
1.2.3 ENMD-2076
1.2.4 Ilorasertib
1.2.5 Others
1.3 Downstream Application of Aurora Kinase A
1.3.1 Ovarian Cancer
1.3.2 Anaplastic Large Cell Lymphoma
1.3.3 Brain Tumor
1.3.4 Others
1.4 Development History of Aurora Kinase A
1.5 Market Status and Trend of Aurora Kinase A 2013-2023
1.5.1 Europe Aurora Kinase A Market Status and Trend 2013-2023
1.5.2 Regional Aurora Kinase A Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Aurora Kinase A in Europe 2013-2017
2.2 Consumption Market of Aurora Kinase A in Europe by Regions
2.2.1 Consumption Volume of Aurora Kinase A in Europe by Regions
2.2.2 Revenue of Aurora Kinase A in Europe by Regions
2.3 Market Analysis of Aurora Kinase A in Europe by Regions
2.3.1 Market Analysis of Aurora Kinase A in Germany 2013-2017
2.3.2 Market Analysis of Aurora Kinase A in United Kingdom 2013-2017
2.3.3 Market Analysis of Aurora Kinase A in France 2013-2017
2.3.4 Market Analysis of Aurora Kinase A in Italy 2013-2017
2.3.5 Market Analysis of Aurora Kinase A in Spain 2013-2017
2.3.6 Market Analysis of Aurora Kinase A in Benelux 2013-2017
2.3.7 Market Analysis of Aurora Kinase A in Russia 2013-2017
2.4 Market Development Forecast of Aurora Kinase A in Europe 2018-2023
2.4.1 Market Development Forecast of Aurora Kinase A in Europe 2018-2023
2.4.2 Market Development Forecast of Aurora Kinase A by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Aurora Kinase A in Europe by Types
3.1.2 Revenue of Aurora Kinase A in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Aurora Kinase A in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Aurora Kinase A in Europe by Downstream Industry
4.2 Demand Volume of Aurora Kinase A by Downstream Industry in Major Countries
4.2.1 Demand Volume of Aurora Kinase A by Downstream Industry in Germany
4.2.2 Demand Volume of Aurora Kinase A by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Aurora Kinase A by Downstream Industry in France
4.2.4 Demand Volume of Aurora Kinase A by Downstream Industry in Italy
4.2.5 Demand Volume of Aurora Kinase A by Downstream Industry in Spain
4.2.6 Demand Volume of Aurora Kinase A by Downstream Industry in Benelux
4.2.7 Demand Volume of Aurora Kinase A by Downstream Industry in Russia
4.3 Market Forecast of Aurora Kinase A in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AURORA KINASE A
5.1 Europe Economy Situation and Trend Overview
5.2 Aurora Kinase A Downstream Industry Situation and Trend Overview
CHAPTER 6 AURORA KINASE A MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Aurora Kinase A in Europe by Major Players
6.2 Revenue of Aurora Kinase A in Europe by Major Players
6.3 Basic Information of Aurora Kinase A by Major Players
6.3.1 Headquarters Location and Established Time of Aurora Kinase A Major Players
6.3.2 Employees and Revenue Level of Aurora Kinase A Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 AURORA KINASE A MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AbbVie Inc.
7.1.1 Company profile
7.1.2 Representative Aurora Kinase A Product
7.1.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of AbbVie Inc.
7.2 Amgen Inc.
7.2.1 Company profile
7.2.2 Representative Aurora Kinase A Product
7.2.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Amgen Inc.
7.3 Astex Pharmaceuticals, Inc.
7.3.1 Company profile
7.3.2 Representative Aurora Kinase A Product
7.3.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Astex Pharmaceuticals, Inc.
7.4 CASI Pharmaceuticals Inc.
7.4.1 Company profile
7.4.2 Representative Aurora Kinase A Product
7.4.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of CASI Pharmaceuticals Inc.
7.5 Merck & Co., Inc.
7.5.1 Company profile
7.5.2 Representative Aurora Kinase A Product
7.5.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.6 Millennium Pharmaceuticals, Inc.
7.6.1 Company profile
7.6.2 Representative Aurora Kinase A Product
7.6.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals, Inc.
7.7 Sanofi
7.7.1 Company profile
7.7.2 Representative Aurora Kinase A Product
7.7.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Sanofi
7.8 Sareum Holdings Plc
7.8.1 Company profile
7.8.2 Representative Aurora Kinase A Product
7.8.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Sareum Holdings Plc
7.9 Sigma-Tau S.p.A.
7.9.1 Company profile
7.9.2 Representative Aurora Kinase A Product
7.9.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Sigma-Tau S.p.A.
7.10 Taiho Pharmaceutical Co., Ltd.
7.10.1 Company profile
7.10.2 Representative Aurora Kinase A Product
7.10.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Taiho Pharmaceutical Co., Ltd.
7.11 Vertex Pharmaceuticals Incorporated
7.11.1 Company profile
7.11.2 Representative Aurora Kinase A Product
7.11.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Vertex Pharmaceuticals Incorporated
7.12 Vichem Chemie Research Ltd.
7.12.1 Company profile
7.12.2 Representative Aurora Kinase A Product
7.12.3 Aurora Kinase A Sales, Revenue, Price and Gross Margin of Vichem Chemie Research Ltd.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AURORA KINASE A
8.1 Industry Chain of Aurora Kinase A
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AURORA KINASE A
9.1 Cost Structure Analysis of Aurora Kinase A
9.2 Raw Materials Cost Analysis of Aurora Kinase A
9.3 Labor Cost Analysis of Aurora Kinase A
9.4 Manufacturing Expenses Analysis of Aurora Kinase A
CHAPTER 10 MARKETING STATUS ANALYSIS OF AURORA KINASE A
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
